Trial reportEuropean journal of nuclear medicine and molecular imaging2017
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.European journal of nuclear medicine and molecular imaging · 2020Guideline
- Review
- The utility ofThyroid research · 2025Article
- Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.Reviews in endocrine & metabolic disorders · 2024Review
- Acetate-Mediated Odorant Receptor OR51E2 Activation Results in Calcitonin Secretion in Parafollicular C-Cells: A Novel Diagnostic Target of Human Medullary Thyroid Cancer.Biomedicines · 2023Article
- The current status and future prospects for molecular imaging-guided precision surgery.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.Endocrine · 2022Review
- Systematic review and meta-analysis of the diagnostic value of radionuclide imaging for thyroid nodules.Gland surgery · 2021Article
- Role of Peptides in Diagnostics.International journal of molecular sciences · 2021Review
- Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.Annals of nuclear medicine · 2021Article
- Clinical relevance ofRadiology and oncology · 2020Article
- Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.Journal of clinical medicine · 2019Review
- Article
- Medullary Thyroid Carcinoma: An Update on Imaging.Journal of thyroid research · 2019Review
- Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Review
- Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.Annals of nuclear medicine · 2018Review
- Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.European thyroid journal · 2018Article
- The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017Review
- SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?European journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to prospectively compare the detection rate of
methodsFifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent
resultsPET/CT evidenced recurrence in 14 of 15 patients. There were 13 true positive (TP), 1 true negative (TN), 1 false positive (FP) and no false negative (FN) cases, resulting in a sensitivity and accuracy of 100% and 93%. SPECT/CT was positive in 6 of 15 cases. There were 6 TP, 2 TN, 7 FN and no FP cases, resulting in a sensitivity of 46% and accuracy of 53%. CI procedures detected tumor lesions in 14 of 15 patients. There were 13 TP, 1TN, 1 FP and no FN cases with a sensitivity of 100% and accuracy of 93%. A significantly higher number of lesions was detected by PET/CT (112 lesions, p = 0.005) and CI (109 lesions, p = 0.005) in comparison to SPECT/CT (16 lesions). There was no significant difference between PET/CT and CI for the total number of detected lesions (p = 0.734). PET/CT detected more lesions than SPECT/CT regardless of the organ. PET/CT detected more bone lesions but missed some neck nodal metastases evidenced by CI. The number of lesions per region demonstrated by PET/CT and CI were similar in the other sites.
conclusion
Indexed as
Identifiers
28429044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.